Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing targeted therapies for genetically driven neuromuscular diseases. Its FORCE platform is designed to deliver therapeutic payloads to muscle tissue and the central nervous system using TfR1-mediated delivery, with programs focused on Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral dystrophy, and Pompe disease.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead therapeutic programs in DM1, DMD, FSHD and Pompe disease advancing through preclinical and clinical development.
A modular delivery platform that uses TfR1 targeting to transport oligonucleotides, enzymes and other payloads to muscle and CNS.
Earlier-stage programs for CNS, rare skeletal muscle, cardiac and metabolic muscle diseases.
Customers
Dyne does not yet sell approved products, so its near-term customers are not patients but regulators, clinical investigators, trial sites, and future commercial payers. If approved, its end customers would be patients with rare neuromuscular diseases and the physicians who treat them, with reimbursement decisions heavily influenced by specialty payers.
Patients with genetically driven muscle diseases who would use Dyne's therapies if approved, seeking functional improvement and disease modification.
Neurologists, neuromuscular specialists and metabolic disease physicians who diagnose, prescribe and monitor treatment.
CMS, private insurers and utilization management groups that decide coverage and access for high-cost specialty drugs.
Trial sites, CROs and investigators that execute preclinical and clinical development programs.
Biopharma partners that could support development, licensing or commercialization in selected indications.
Strategy
Dyne's strategy is to use its FORCE platform to build a portfolio of differentiated therapies for genetically defined neuromuscular diseases with clear regulatory paths and high unmet need. Near term, the company is focused on advancing clinical programs, expanding the platform into additional muscle and CNS indications, and preserving access to capital until it can reach commercialization or partnership milestones.
Clinical proof-of-concept is the main value driver for a pre-revenue biotech and de-risks the platform.
A broader platform can create multiple shots on goal and improve partnering optionality.
The company expects continued losses and needs funding to sustain R&D and commercialization readiness.
Geography
Dyne is headquartered in the United States and operates as a U.S.-based clinical-stage biotech with global commercial rights to its programs. The company has not disclosed country-level revenue because it has not generated product revenue, and its business is currently concentrated in U.S.-based research, clinical development and regulatory activities.
Risks
Dyne is a pre-revenue biotech with significant operating losses, so its business depends on successful clinical development, regulatory approval and access to capital. It also relies heavily on third-party CROs, CMOs and other vendors, while facing intense competition from other rare-disease and delivery-platform developers.
- Capital dilution or financing shortfallImpact: HighLikelihood: High
The company expects continued losses and will need external funding before product revenue begins.
Exposure: Company-wide
- Clinical development failureImpact: HighLikelihood: Medium
Lead programs are still in early stages, and efficacy or safety issues could halt or delay approval.
Exposure - Third-party manufacturing and trial executionImpact: MediumLikelihood: Medium
Clinical and manufacturing operations depend on external vendors that can disrupt timelines or raise costs.
Exposure - Competitive displacementImpact: MediumLikelihood: Medium
Other companies may develop better or earlier therapies for the same rare diseases or delivery problem.
Exposure: Neuromuscular disease pipeline
- Reimbursement and market accessImpact: MediumLikelihood: Medium
Even approved rare-disease therapies can face restrictive coverage and utilization management.
Exposure: Future commercial products
Accounting
Judgemental itemsClinical trial and manufacturing invoices often lag activity, so estimates affect expense timing and liabilities.
Impact: Can materially shift quarterly operating loss and accrued liabilities
Employee equity awards are a meaningful cost for a development-stage biotech and affect GAAP losses.
Impact: Impacts operating expenses and net loss without affecting cash burn
Any partnering deal would require judgment on timing and recognition of upfront, milestone or royalty income.
Impact: Could create lumpy revenue recognition if partnerships are signed
Similar listed companies
Publicly listed companies with a comparable business focus.
Solid Biosciences Inc.
SLDB · Biological Products, (No Diagnostic Substances)
Entrada Therapeutics, Inc.
TRDA · Pharmaceutical Preparations
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines designed to reach intracellular targets that have historically been difficult to access.
Capricor Therapeutics, Inc
CAPR · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Sarepta Therapeutics, Inc.
SRPT · Pharmaceutical Preparations
Sarepta Therapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy,…
Kyverna Therapeutics, Inc.
KYTX · Biological Products, (No Diagnostic Substances)
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases.
Last updated: 24/09/2026